ABUS vs. ARMP
ABUS (Arbutus Biopharma Corporation) and ARMP (Armata Pharmaceuticals Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 10 years, ABUS returned 2.85%/yr vs -29.10%/yr for ARMP. At a 0.06 correlation, their price movements are largely independent.
Performance
ABUS vs. ARMP - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, ABUS achieves a -7.48% return, which is significantly lower than ARMP's 11.62% return. Over the past 10 years, ABUS has outperformed ARMP with an annualized return of 2.85%, while ARMP has yielded a comparatively lower -29.10% annualized return.
ABUS
- 1D
- -1.55%
- 1M
- 2.30%
- YTD
- -7.48%
- 6M
- -4.91%
- 1Y
- 30.50%
- 3Y*
- 22.68%
- 5Y*
- 6.23%
- 10Y*
- 2.85%
ARMP
- 1D
- 2.04%
- 1M
- -16.15%
- YTD
- 11.62%
- 6M
- 11.62%
- 1Y
- 280.98%
- 3Y*
- 72.32%
- 5Y*
- 10.22%
- 10Y*
- -29.10%
ABUS vs. ARMP - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
ABUS Arbutus Biopharma Corporation | -7.48% | 47.09% | 30.80% | 7.30% | -40.10% | 9.58% | 27.70% | -27.42% | -24.16% | 106.12% |
ARMP Armata Pharmaceuticals Inc. | 11.62% | 239.46% | -42.90% | 161.29% | -77.37% | 83.59% | -8.16% | 12.53% | -79.57% | -77.05% |
Correlation
The correlation between ABUS and ARMP is 0.11, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.11 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.10 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.06 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.04 |
Correlation (All Time) Calculated using the full available price history since Aug 3, 2015 | 0.06 |
Fundamentals
ABUS:
$868.70M
ARMP:
$256.08M
ABUS:
$0.83
ARMP:
-$7.79
ABUS:
4.48
ARMP:
57.66
ABUS:
$191.45M
ARMP:
$4.41M
ABUS:
$12.30M
ARMP:
$3.26M
ABUS:
$156.13M
ARMP:
-$27.14M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
ABUS vs. ARMP — Risk / Return Rank
ABUS
ARMP
ABUS vs. ARMP - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Arbutus Biopharma Corporation (ABUS) and Armata Pharmaceuticals Inc. (ARMP). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ABUS | ARMP | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.33 | ||
| Sortino ratioReturn per unit of downside risk | -2.35 | ||
| Omega ratioGain probability vs. loss probability | 1.14 | 1.43 | -0.28 |
| Calmar ratioReturn relative to maximum drawdown | 1.18 | 5.23 | -4.04 |
| Martin ratioReturn relative to average drawdown | 3.02 | 13.22 | -10.20 |
Loading charts...
Drawdowns
ABUS vs. ARMP - Drawdown Comparison
The maximum ABUS drawdown since its inception was -92.96%, smaller than the maximum ARMP drawdown of -99.98%. Use the drawdown chart below to compare losses from any high point for ABUS and ARMP.
Loading charts...
Drawdown Indicators
| ABUS | ARMP | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -92.96% | -99.98% | +7.02% |
Max Drawdown (1Y)Largest decline over 1 year | -25.86% | -54.12% | +28.26% |
Max Drawdown (3Y)Largest decline over 3 years | -36.84% | -79.22% | +42.38% |
Max Drawdown (5Y)Largest decline over 5 years | -63.42% | -85.70% | +22.28% |
Max Drawdown (10Y)Largest decline over 10 years | -92.96% | -99.68% | +6.72% |
Current DrawdownCurrent decline from peak | -63.97% | -99.86% | +35.89% |
Average DrawdownAverage peak-to-trough decline | -69.03% | -82.82% | +13.79% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 10.18% | 21.36% | -11.18% |
Volatility
ABUS vs. ARMP - Volatility Comparison
The current volatility for Arbutus Biopharma Corporation (ABUS) is 11.58%, while Armata Pharmaceuticals Inc. (ARMP) has a volatility of 14.22%. This indicates that ABUS experiences smaller price fluctuations and is considered to be less risky than ARMP based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| ABUS | ARMP | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 11.58% | 14.22% | -2.64% |
Volatility (6M)Calculated over the trailing 6-month period | 34.61% | 74.14% | -39.53% |
Volatility (1Y)Calculated over the trailing 1-year period | 46.14% | 141.73% | -95.59% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 54.61% | 113.71% | -59.10% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 85.43% | 110.32% | -24.89% |
Dividends
ABUS vs. ARMP - Dividend Comparison
Neither ABUS nor ARMP has paid dividends to shareholders.
Financials
ABUS vs. ARMP - Financials Comparison
This section allows you to compare key financial metrics between Arbutus Biopharma Corporation and Armata Pharmaceuticals Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
ABUS and ARMP have a correlation of 0.11, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
ARMP has higher volatility (14.22%) compared to ABUS (11.58%). In terms of maximum drawdown, ABUS dropped -92.96% vs ARMP's -99.98%.
ARMP currently has the higher Sharpe Ratio (2.00 vs 0.66), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for ABUS and ARMP
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer